Top

Published in:

01-04-2010 | Original Research Article

Effect of the Common -866G/A Polymorphism of the Uncoupling Protein 2 Gene on Weight Loss and Body Composition under Sibutramine Therapy in an Obese Taiwanese Population

Authors: Tun-Jen Hsiao, Lawrence Shih-Hsin Wu, Yuchi Hwang, Shih-Yi Huang, Dr Eugene Lin

Published in: Molecular Diagnosis & Therapy | Issue 2/2010

Abstract

Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene.

Objective: In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population.

Methods: The study included 131 obese patients, 44 in the placebo group and 87 in the sibutramine group. We assessed the measures of weight loss and body fat reduction at the end of a 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and body fat percentage at baseline as covariates.

Results and Conclusion: By comparing the placebo and sibutramine groups with ANCOVA, our data showed a strong effect of sibutramine on weight loss in the combined UCP2 -866 AA+GA genotype groups (p<0.001). Similarly, a strong effect of sibutramine on body fat percentage loss was found for individuals with the AA or GA genotypes (p<0.001). In contrast, sibutramine had no significant effect on weight loss (p = 0.063) or body fat percentage loss (p = 0.194) for individuals with the wild-type GG genotype, compared with the placebo group of the same genotype. Moreover, a potential gene-gene interaction between UCP2 and GNB3 was identified by multiple linear regression models for the weight loss (p < 0.001) and for the percent fat loss (p = 0.031) in response to sibutramine. The results suggest that the UCP2 gene may contribute to weight loss and fat change in response to sibutramine therapy in obese Taiwanese patients.

Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9(12): 2161–73PubMedCrossRef

Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology 2008; 135(4): 1142–54PubMedCrossRef

Hauner H, Meier M, Jöckel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13(8): 453–9PubMedCrossRef

Hsiao DJ, Wu LS, Huang SY, et al. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet Genomics 2009; 19(9): 730–3PubMedCrossRef

Vazquez Roque MI, Camilleri M, Clark MM, et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol 2007; 5(7): 829–37CrossRef

Dalgaard LT, Pedersen O. Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and type II diabetes. Diabetologia 2001; 44(8): 946–65PubMedCrossRef

Yoon Y, Park BL, Cha MH, et al. Effects of genetic polymorphisms of UCP2 and UCP3 on very low calorie diet-induced body fat reduction in Korean female subjects. Biochem Biophys Res Commun 2007; 359(3): 451–6PubMedCrossRef

Esterbauer H, Schneitler C, Oberkofler H, et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28(2): 178–83PubMedCrossRef

Krempler F, Esterbauer H, Weitgasser R, et al. A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 2002; 51(11): 3331–5PubMedCrossRef

10.

Jun HS, Kim IK, Lee HJ, et al. Effects of UCP2 and UCP3 variants on the manifestation of overweight in Korean children. Obesity (Silver Spring) 2009; 17(2): 355–62

11.

Kovacs P, Ma L, Hanson RL, et al. Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians. Diabetologia 2005; 48(11): 2292–5PubMedCrossRef

12.

D’Adamo M, Perego L, Cardellini M, et al. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes 2004; 53(7): 1905–10PubMedCrossRef

13.

Wang H, Chu WS, Lu T, et al. Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab 2004; 286(1): E1–7PubMedCrossRef

14.

Bulotta A, Ludovico O, Coco A, et al. The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J Clin Endocrinol Metab 2005; 90(2): 1176–80PubMedCrossRef

15.

Bell JT, Wallace C, Dobson R, et al. Two-dimensional genome-scan identifies novel epistatic loci for essential hypertension. Hum Mol Genet 2006; 15(18): 1365–74PubMedCrossRef

16.

Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies. Nat Rev Genet 2004; 5(8): 618–25PubMedCrossRef

17.

Lin E, Hwang Y, Liang KH, et al. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 2007; 8(1): 75–83PubMedCrossRef

18.

Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 2007; 8(10): 1327–35PubMedCrossRef

19.

Lin E, Hsu SY. A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. Pharmacogenomics 2009; 10(1): 35–42PubMedCrossRef

20.

Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27(5): 1182–6PubMedCrossRef

21.

Lin E, Pei D, Huang YJ, et al. Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet Test Mol Biomarkers 2009; 13(4): 485–93PubMedCrossRef

22.

Wu LS, Hsieh CH, Pei D, et al. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009 Nov; 24(11): 3360–6PubMedCrossRef

23.

Sesti G, Cardellini M, Marini MA, et al. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucosetolerant subjects. Diabetes 2003; 52(5): 1280–3PubMedCrossRef

24.

Getty L, Hamilton-Wessler M, Ader M, et al. Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Diabetes 1998; 47(12): 1941–7PubMedCrossRef

25.

Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(7): 1167–72PubMedCrossRef

26.

Huang LC, Hsu SY, Lin E. A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data. J Transl Med 2009; 7(1): 81PubMedCrossRef

Title: Effect of the Common -866G/A Polymorphism of the Uncoupling Protein 2 Gene on Weight Loss and Body Composition under Sibutramine Therapy in an Obese Taiwanese Population
Authors: Tun-Jen Hsiao
Lawrence Shih-Hsin Wu
Yuchi Hwang
Shih-Yi Huang
Dr Eugene Lin
Publication date: 01-04-2010
Publisher: Springer International Publishing
Published in: Molecular Diagnosis & Therapy / Issue 2/2010
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI: https://doi.org/10.1007/BF03256359

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of the Common -866G/A Polymorphism of the Uncoupling Protein 2 Gene on Weight Loss and Body Composition under Sibutramine Therapy in an Obese Taiwanese Population

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Development of Primer-Special TaqMan® PCR

Only Connect

Interleukin-10 Gene Polymorphisms Influence Susceptibility to Cachexia in Patients with Low-Third Gastric Cancer in a Chinese Population

Prevalence of Salmonella typhi among Patients with Febrile Illness in Rural and Peri-Urban Populations of Vellore District, as Determined by Nested PCR Targeting the Flagellin Gene

A Case of a Novel PML/RARA Short Fusion Transcript with Truncated Transcription Variant 2 of the RARA Gene

Molecular Medicine Tri-Conference 2010

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page